PhysIQ

PhysIQ, founded in 2013 by Gary Conkright, emerged from a project at the United States Department of Energy's Argonne National Laboratory. Conkright, with a background in venture capital and technology commercialization, leveraged his experience to steer the company's focus towards transforming healthcare through data analytics. The company has established a significant presence in the digital health sector, securing multiple FDA clearances for its proprietary analytics platform. A notable milestone includes a multi-million dollar contract with the U.S. Department of Defense to develop a system for the early detection of viral infections.

The core of PhysIQ's business is a device-agnostic, enterprise-grade platform that remotely monitors patients by collecting and analyzing data from wearable biosensors. This platform is designed to serve two primary client segments: healthcare providers and life sciences companies. For healthcare systems, the technology enables proactive care by identifying subtle changes in a patient's physiology that may indicate a health decline, thereby aiming to reduce hospital readmissions. In the life sciences realm, PhysIQ's solution supports decentralized clinical trials, allowing for the continuous collection of patient data in real-world settings, which can lead to more efficient and faster drug development. The business model operates on a B2B basis, generating revenue by providing its platform and analytical insights to these enterprise clients.

PhysIQ's platform ingests continuous data streams from various FDA-cleared wearable sensors, tracking metrics such as heart rate, respiration rate, and activity levels. The key differentiator lies in its personalized analytics, which first establish a patient-specific baseline and then use artificial intelligence to detect deviations from that norm. This approach moves beyond simple data alerts to provide contextualized insights into a patient's health trajectory. The system has received FDA 510(k) clearance for its Heart Failure and Atrial Fibrillation detection analytics, as well as its platform for analyzing vital signs, underscoring its clinical validity.

Keywords: remote patient monitoring, digital health, clinical trials, physiological analytics, wearable sensors, healthcare data, FDA cleared, artificial intelligence, predictive analytics, life sciences